(0.37%) 5 040.93 points
(0.46%) 37 928 points
(0.35%) 15 739 points
(0.40%) $83.02
(2.10%) $1.748
(0.42%) $2 398.40
(0.12%) $28.44
(0.17%) $955.80
(0.15%) $0.938
(0.35%) $11.03
(-0.03%) $0.803
(0.10%) $94.15
Live Chart Being Loaded With Signals
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19)...
Stats | |
---|---|
Today's Volume | 441 087 |
Average Volume | 2.95M |
Market Cap | 149.00M |
EPS | $-0.0121 ( 2024-04-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.50 |
ATR14 | $0.00100 (0.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Lalezari Jacob P | Buy | 3 000 000 | Non-qualified stock option (right to buy) |
2024-02-01 | Cohen Mitchell | Buy | 0 | |
2024-01-03 | Migliarese Antonio | Buy | 1 000 000 | Non-qualified stock option (right to buy) |
2024-01-03 | Migliarese Antonio | Buy | 630 222 | Non-qualified stock option (right to buy) |
2024-01-03 | Migliarese Antonio | Buy | 100 000 | Non-qualified stock option (right to buy) |
INSIDER POWER |
---|
73.84 |
Last 91 transactions |
Buy: 23 178 436 | Sell: 2 742 551 |
Volume Correlation
CytoDyn Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CytoDyn Inc. Correlation - Currency/Commodity
CytoDyn Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-175 000 (0.00 %) |
EPS: | $-0.0954 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-10 000.00 (0.00 %) |
EPS: | $-0.0203 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-12 000.00 (0.00 %) |
EPS: | $-0.0191 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-17.93M (0.00 %) |
EPS: | $-0.0334 |
Financial Reports:
No articles found.
CytoDyn Inc.
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators